Targeting Antigens in the Development of Vaccines for Cancer
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope
Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.
Retrospective Data Show Real-World Disparities in Black vs White Patients With Endometrioid Endometrial Carcinoma
SEER data showed that Black patients endometrioid endometrial carcinoma had higher 5-year cancer-related death rates compared with their White counterparts.
Communication and Education Are Key for CAR T-Cell Therapy in LBCL
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Tislelizumab/Chemo Yields Antitumor Activity in Advanced Cervical Cancer
A phase 2 trial showed favorable antitumor activity when tislelizumab plus chemotherapy was used for patients with locally advaned cervical cancer.
Mirvetuximab Yields HRQOL Improvement in FRα-Positive Ovarian Cancer
Patient reported outcomes from the phase 3 MIRASOL trial showed improvement when mirvetuximab was used vs standard of care in folate receptor-alpha positive ovarian cancer resistant ovarian cancer.
Olaparib/Cediranib Does Not Show Survival Benefit in Advanced Ovarian Cancer
The phase 2/3 NRG-GY005 trial assessing olaparib plus dediranib did not improve survival vs standard of care in ovarian cancer.
Disparities in Cervical Cancer by Socioeconomic Status
Study finds social determinants of health linked to variations in cervical cancer rates.
Dostarlimab/Chemo Significantly Improves OS in Advanced Endometrial Cancer
The survival benefit with dostarlimab/chemotherapy was deemed unprecedented in patients with microsatellite instability high primary advanced or recurrent endometrial cancer.
Pembrolizumab Combo Yields Survival Benefit in Endometrial Cancer
Results from the KEYNOTE-868 trial showed a favorable benefit of pembrolizumab plus chemotherapy across endometrial cancer subgroups.
Considering Age/Comorbidities in CAR T-Cell Therapy Consultation for LBCL
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
Ide-Cel Receives Favorable ODAC Vote for R/R Multiple Myeloma
The ODAC meeting concluded that ide-cel showed a favorable risk/benefit profile for patients with pretreated relapsed/refractory multiple myeloma.
ODAC Casts 11 to 0 Vote in Favor of Cilta-Cel in R/R Multiple Myeloma
ODAC voted on the risk/benefit ratio of cilta-cel vs standard of care for patients with lenalidomide-refractory multiple myeloma.
FDA Accepts NDA for Ensartinib in Metastatic ALK-Positive NSCLC
The regulatory agency set an action date of December 28, 2024 for ensartinib as a treatment for those with ALK-positive non–small cell lung cancer.
Survival Benefit Observed With Targeted Therapies in NSCLC Cohort Study
A cohort study for patients with non–small cell lung cancer found an overall survival benefit when targeted therapies were utilized.
Team Effort Is Needed to Expand CAR T-Cell Therapy Access for LBCL
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
FDA Approves Liso-Cel for Relapsed/Refractory CLL/SLL
Patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma can now receive lisocabtagene maraleucel after the FDA approved the drug, which was based on the phase 1/2 TRANSCEND CLL trial.
FDA Approves Second-Line Tislelizumab Monotherapy in Esophageal Cancer
Results from the phase 3 RATIONALE 302 trial led to the approval of tislelizumab for patients with unresectable or metastatic esophageal squamous cell carcinoma.
FDA ODAC Votes in Favor of Imetelstat Benefits Vs Risks in Lower-Risk MDS
Members of the committee reviewed findings from the phase 2/3 IMerge trial assessing imetelstat in patients with transfusion-dependent anemia in myelodysplastic syndromes.
Bivalent CAR T-Cell Therapy Shows Tumor Shrinkage in Recurrent Glioblastoma
Findings highlighted tumor reductions in patients with recurrent glioblastoma who received CART-EGFR-IL13Rα2 cells at 2 dose levels.
Nivolumab/Chemo Approval Adds Options for Urothelial Carcinoma, Expert Says
Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the recent approval of nivolumab plus chemotherapy for patients with unresectable or metastatic urothelial carcinoma.
Evaluating Secondary Primary Malignancy Risk After CAR T-cell Therapy
In 2023, the FDA issued a warning on secondary primary malignancies after treatment with CAR T-cell therapy.
ASH 2023: The Most Relevant Multiple Myeloma Data Presented
Joshua Richter, MD, led an enthusiastic panel with his colleagues in the multiple myeloma space following the 2023 ASH Annual Meeting and Exposition.
Nivolumab/Chemo Yields Meaningful Survival in Advanced Gastric/GEJ Cancer
Findings from the phase 3 CheckMate 649 trial support nivolumab plus chemotherapy as a standard frontline therapy for patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma.
CAR T-Cell Therapy Access Expansion for LBCL Sees “Early Success”
It may be applicable to administer CAR T-cell therapy to patients with large B-cell lymphoma in a community or outpatient setting.
Assessing Other Options Aside from Surgery Shows “Promise” in Breast Cancer
Targeted imaging and biopsy may accurately identify patients with breast cancer who do not have residual disease, according to Henry Kuerer, MD, PhD, FACS, CMQ.
Data Support Impact of Precision Medicine in Managing Prostate Cancer
Leonard G. Gomella, MD, FACS, discusses new clinical trials that are evaluating novel targeted therapy options for those with prostate cancer.
Robotic-Assisted Mastectomy Has Potential, but Is a Cautionary Tale
The use of a robot to aid in nipple-sparing surgery has been a controversial topic, although ongoing trials may show its potential.
Brentuximab Vedotin Combo Significantly Improves Survival in R/R DLBCL
Treatment with brentuximab vedotin, lenalidomide, and rituximab yielded a progression-free survival benefit in the phase 3 ECHELON-3 trial.
Ide-cel Improves HRQOL Vs Standard Treatment in R/R Multiple Myeloma
Patient-reported outcomes support the clinical benefits of ide-cel among patients with relapsed/refractory multiple myeloma.
